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One critical quality attribute of therapeutic antibodies is the glycosylation pattern at the Fc region.We combined 
genome editing of CHO cells and protein engineering of the IgG Fc region to allow antibodies presenting high 
level of galactosylation or exclusively α-2,6 sialylation. To generate IgG with high α-2,6 sialylation, we combined 
amino acid mutations in the Fc region of IgG and introduction of α-2,6 sialyltransferase in CHO to produce IgGs 
with significant levels of both α-2,6 and α-2,3 sialylation. Furthermore, to produce exclusively α-2,6 sialylation 
IgG in CHO, CRISPR/Cas9 was implemented to disrupt two dominant α-2,3 sialyltransferase genes (ST3GAL4 
and ST3GAL6), then α-2,6 sialyltransferewas introduced in a α-2,3 sialylation knockout cell line. Notably, no α-
2,3 linked sialic acids of IgG produced from the α-2,3 sialyltransferase knockout-α-2,6 sialyltransferase 
overexpression pools were detected by HPLC sialic acid quantification after the α-2,3 linkage specific sialidase 
cleavage. Finally, glycosylation analysis of IgG with four amino acid mutations generated by an α-2,3 
sialyltransferase knockout-α-2,6 sialyltransferase overexpression stable CHO clone rendered >75% of sialylated 
glycans, among which 62.5 % was biantennary disialylated glycans.   
       
Interestingly, the disruption of two α-2,3 sialyltransferases (ST3GAL4 and ST3GAL6) from CHO cells in 
conjunction with protein engineering of the Fc region produced IgGs with a great majority of bigalactosylated 
and fucosylated (G2F) glycoforms. Expression of the IgG with engineered Fc region (F241A) in triple gene 
knockout (FuT8-/-, ST3GAL4-/- and ST3GAL6-/-) CHO cells lowered the galactosylation content to 65% 
bigalactosylated glycoform (G2). However, overexpression of IgGs with four amino acid substitutions from the α-
2,3 sialyltransferases knocked out CHO cells reconstituted the fraction of G2 glycoform back up to 
approximately 80%.  Collectively, this study, to our knowledge, is the first attempt for generating highly 
galactosylated or solely α-2,6 sialylated N-glycans on antibodies in vivo, allowing researchers in both academia 
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